Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial

This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza Vaccine (Split virion) I.P. (TetIV), containing two strains each of influenza A and B, developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkar, Sumantra, Bokade, Chandrakant, Garg, Kapil, Kumar, Ravi, Sanmukhani, Jayesh, Mittal, Ravindra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993130/
https://www.ncbi.nlm.nih.gov/pubmed/32845782
http://dx.doi.org/10.1080/21645515.2020.1794683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993130/
https://www.ncbi.nlm.nih.gov/pubmed/32845782
http://dx.doi.org/10.1080/21645515.2020.1794683

Ejemplares similares